7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Cancer Care

Dry Mouth, Fatigue and Blood Counts After Lutetium-177 PSMA Therapy: What the Team Watches

23 min read
Dry Mouth, Fatigue and Blood Counts After Lutetium-177 PSMA Therapy: What the Team Watches

Key Takeaways

  • Dry mouth happens because salivary glands display the same PSMA protein the drug targets, and it affected about 39% of treated men in the VISION trial.
  • Fatigue was the most common effect in VISION at about 43%, usually peaking within the first week or two after each cycle and easing before the next.
  • Blood counts typically dip in the weeks after infusion, which is why a complete blood count is drawn before every cycle to decide whether to proceed, delay or stop.
  • Lutetium-177 beta particles travel only about two millimeters in tissue, which is why nearby healthy tissue is largely spared but PSMA-rich organs are not.
  • In VISION, median overall survival was 15.3 months with treatment versus 11.3 months with standard care alone; a median is a midpoint, not an individual forecast.
  • A PSMA PET scan uses a diagnostic trace amount of a different isotope and does not cause the dry mouth, fatigue or blood count changes seen with treatment.
Quick Answer

The most common lutetium PSMA therapy side effects are dry mouth, fatigue, nausea and lower blood counts, because the radioactive drug binds not only to prostate cancer cells but also to salivary glands and reaches the bone marrow. Most effects are mild to moderate and are monitored with blood tests before each treatment cycle, though some, such as dry mouth, can persist. Your treating team decides whether to continue, delay or stop.

The infusion itself takes minutes. What surprises many men is what comes afterward: the odd stickiness in the mouth on the drive home, the tiredness that arrives a few days later like a tide, and the folder of blood test results that suddenly matters more than any scan. One patient described keeping a water bottle in every room of the house for the first time in his life.

Lutetium-177 PSMA therapy is a targeted form of internal radiation used for advanced prostate cancer that has spread and stopped responding to hormone-based treatment. It is precise, but it is not perfectly selective, and the places it lands by mistake explain nearly every one of the lutetium PSMA therapy side effects patients ask about.

This explainer walks through what the treating team is actually watching, why those particular organs are involved, what typical timelines look like in the published trials, and which signs should prompt a phone call rather than a wait-and-see.

What lutetium PSMA therapy actually does inside the body

PSMA stands for prostate-specific membrane antigen, a protein that sits on the outer surface of most prostate cancer cells in far greater numbers than on healthy prostate tissue. Lutetium-177 is a radioactive metal. Chemists attach it to a small molecule, most often called PSMA-617, that seeks out and locks onto that protein. The result is a radiopharmaceutical: a drug whose active ingredient is radiation delivered to a chosen address.

Once infused into a vein, the compound circulates, finds PSMA-rich cells and binds. Lutetium-177 then releases beta particles, a type of radiation that travels only about two millimeters through tissue, roughly the thickness of a coin. That short range is the whole point. Cancer cells and their immediate neighbors receive a concentrated dose while tissue a few millimeters away is largely spared. The isotope also emits a small amount of gamma radiation, which is why teams can take images after treatment to see where the drug went.

Here is the catch that explains the side effects. PSMA is not truly prostate-specific. The salivary glands, the tear glands, the kidneys and parts of the small intestine also display it, and the drug binds there too. Radiation that circulates in the blood also passes through the bone marrow, the spongy tissue that manufactures blood cells. Dry mouth, kidney monitoring and falling blood counts are the direct consequences of those unintended stops.

Treatment is given as a course of intravenous infusions spaced several weeks apart, with the number of cycles decided by the team based on how the disease responds and how the body tolerates it. In the VISION trial, the largest randomized study of this therapy, blood tests were repeated before every cycle to decide whether it was safe to proceed.

Who is usually offered lutetium PSMA therapy, and who is asked to wait

The evidence base rests on men with metastatic castration-resistant prostate cancer. That mouthful means the cancer has spread beyond the prostate and keeps growing despite treatment that lowers testosterone to very low levels. In the VISION trial, participants had already received at least one newer hormone-pathway drug and at least one taxane chemotherapy, and every one of them had a PSMA PET scan showing that their tumors displayed the target protein.

Doctor consulting with elderly male patient about food: Who is usually offered lutetium PSMA therapy, and who is asked to wa

That scan is the gatekeeper. If a tumor does not light up on PSMA imaging, the drug has nothing to bind to and the radiation would circulate without a destination. Teams also look for the reverse problem: deposits that show up clearly on a conventional CT scan but not on the PSMA scan, which suggests some of the cancer has lost the target and may not respond.

Men are commonly asked to wait, or offered something else, when:

  • Blood counts are already low from previous chemotherapy or from cancer in the bone marrow, because the treatment would push them lower.
  • Kidney function is reduced, since the kidneys both display PSMA and clear the drug from the body.
  • General fitness is poor enough that a six-month course of treatment and recovery would be hard to tolerate.
  • Current therapy is still controlling the disease, because the trials studied men whose earlier options had already stopped working.
  • Dry mouth or dental disease is already severe.

Alternatives discussed at this stage typically include further chemotherapy, other hormone-pathway agents, radiation to painful sites, a clinical trial or supportive care focused on symptoms. None of these choices is generic. The multidisciplinary team weighs the scan pattern, the blood work, the kidneys and, above all, what the patient wants from the months ahead.

Lutetium PSMA therapy side effects at a glance

Numbers help here, because the internet tends to describe this treatment either as side-effect-free or as devastating. Neither matches the trial data. The table below draws on the VISION trial, in which 529 men received lutetium-177 PSMA-617 alongside standard care and 205 received standard care alone. Figures are the share who reported the effect at any severity in the treatment arm.

Side effect Any grade (VISION, treatment arm) Usual onset What the team watches
Fatigue About 43% Days after each cycle Anemia, hydration, sleep, mood
Dry mouth About 39% Within the first cycles, may build Dental health, taste, weight
Nausea About 35% First days after infusion Fluid intake, appetite
Anemia (low red cells) About 32% Weeks after infusion Hemoglobin before each cycle
Low platelets About 17% Weeks after infusion Bruising, bleeding, count trend
Low lymphocytes About 14% Weeks after infusion Infection risk
Kidney-related events About 9% Variable Creatinine, filtration rate

Two features stand out. First, most of these effects were mild or moderate; severe or worse events of any kind occurred in roughly 53% of the treatment group compared with about 38% of the standard-care group, a real but not overwhelming difference in men who were already unwell. Second, the effects cluster in exactly the organs that display PSMA or receive circulating radiation, which is why monitoring can be planned rather than reactive.

Percentages describe populations, not individuals. A man with healthy marrow and kidneys going in may sail through several cycles; another may need a pause after two. The trend in his own results matters more than any table.

Why lutetium 177 causes dry mouth, and what actually helps

Salivary glands display PSMA on their cell surfaces, so the drug docks there just as it does on cancer cells. The glands receive a dose of beta radiation, produce less saliva, and the mouth feels sticky, tastes change, and food can seem harder to swallow. Xerostomia, the medical term for a dry mouth, was reported by roughly 39% of treated men in the VISION trial compared with fewer than 1% in the standard-care group, though it was almost always mild or moderate.

Doctor consulting with older male patient in clinic: Why lutetium 177 causes dry mouth, and what actually helps

Saliva does more than keep the mouth comfortable. It buffers acid, carries minerals that repair enamel and washes bacteria away. A persistently dry mouth raises the risk of tooth decay, gum inflammation and oral thrush, which is why many teams recommend a dental check before the first cycle and gentle, regular care throughout.

Practical measures with reasonable support from dental and cancer-care guidance include:

  • Frequent small sips of water rather than large gulps, and a bottle within reach at night.
  • Sugar-free gum or lozenges to stimulate whatever saliva the glands can still make.
  • Saliva substitute sprays or gels, a class of over-the-counter products your pharmacist or dentist can explain.
  • Avoiding alcohol-based mouthwashes, tobacco and very salty or spicy foods that sting a dry surface.
  • A soft toothbrush, fluoride toothpaste and a humidifier in the bedroom.

Some centers have tried cooling the cheeks with ice packs during the infusion to reduce blood flow to the glands. The evidence for this is mixed and small; it is reasonable to ask about, but it should not be presented as proven. Dry mouth can improve between cycles and after treatment ends, but in some men it persists. Telling the team early, before eating becomes a chore, lets them weigh symptom burden against benefit for the next cycle.

Lu-177 PSMA therapy fatigue: how long does it last?

Fatigue was the single most common complaint in the VISION trial, reported by about 43% of treated men versus about 23% of those on standard care alone. It rarely announces itself on infusion day. More often it settles in over the following days, peaks within the first week or two, and then eases before the next cycle, though many men describe a baseline that drifts lower as cycles accumulate.

Several mechanisms overlap. Radiation triggers an inflammatory response as cells break down, and the body spends energy clearing debris. Red blood cell counts fall in a proportion of men, and fewer red cells means less oxygen delivered to muscles. Nausea and a dry mouth reduce eating and drinking. Advanced cancer itself, months of prior treatment and disrupted sleep add their own weight. Fatigue after cancer treatment, as the National Cancer Institute describes, is different from ordinary tiredness in that rest alone often does not fix it.

What the evidence supports is counterintuitive: gentle, regular physical activity tends to reduce cancer-related fatigue rather than worsen it. A short daily walk, timed for the part of the day with the most energy, is a common starting point. Pacing matters too: planning demanding tasks for better days, accepting help with the rest, and protecting sleep with a consistent routine.

The team, meanwhile, looks for treatable contributors. Hemoglobin is checked before every cycle. Thyroid function, mood, pain control and medication side effects can all masquerade as fatigue. If tiredness is severe enough that you cannot manage basic daily activities, or if it comes with breathlessness, dizziness or a racing heart, that combination points toward anemia or another cause that needs prompt assessment rather than patience.

Blood counts after Lu-177 PSMA: what the team is really watching

Bone marrow is the factory that produces red blood cells, white blood cells and platelets. Lutetium-177 in the bloodstream irradiates the marrow as it passes through, and men whose cancer has spread extensively into bone have marrow that is already under strain. The combined effect is myelosuppression, meaning the marrow makes fewer cells than the body needs.

A complete blood count, the standard test described by MedlinePlus, measures each cell line. In VISION, anemia (low red cells) affected about 32% of treated men, low platelets about 17%, low lymphocytes about 14% and low white cells overall about 13%. Severe versions were less common but not rare: severe anemia in roughly 13%, severe low platelets in about 8%.

Each cell line carries a different risk:

  • Red cells carry oxygen. Falling hemoglobin shows up as fatigue, breathlessness on stairs, pale skin or a pounding heartbeat.
  • Platelets stop bleeding. Low counts can mean easy bruising, nosebleeds, bleeding gums or tiny red pinpricks on the skin.
  • White cells, especially neutrophils, fight infection. Low counts turn an ordinary fever into an urgent problem.

Counts typically dip in the weeks after an infusion and recover before the next one is due; the team draws blood shortly before each cycle and compares it with the last. If a count has not recovered enough, the cycle may be delayed, the amount adjusted or the course stopped. Those thresholds are set by the treating physician, not by a general article, and they depend on the pattern across all three cell lines together.

Men with heavy bone involvement or a long history of chemotherapy are watched most closely, because their marrow has the least reserve. A transfusion is sometimes offered for symptomatic anemia. None of this means treatment has failed; it means the monitoring is doing its job.

Kidneys, gut and appetite: the quieter side effects

The kidneys sit in an awkward position with this therapy. They display PSMA on the cells lining their filtering tubules, and they are also the main exit route for the drug, so they receive radiation twice over. In VISION, kidney-related adverse events were recorded in about 9% of treated men, most mild. Because the trial followed participants for a limited period, the long-term picture is still being gathered; teams therefore measure creatinine and estimated filtration rate before every cycle and periodically afterward.

Hydration is the practical lever. Drinking well before and after the infusion helps the kidneys flush the unbound drug, and frequent urination in the first day or two also lowers the radiation dose the bladder receives. The exact fluid target, and whether any medicine is needed to protect the kidneys, is a decision for the prescribing clinician, particularly in men with heart failure or existing kidney disease where extra fluid is not automatically safe.

The gut contributes its own set of symptoms. Nausea affected about 35% of treated men in VISION, usually in the first few days, and reduced appetite, constipation and diarrhea were also more common than in the comparison group. Anti-sickness medicines exist in several classes and are often prescribed to take before the infusion; the team chooses which one and when. Small, frequent meals, bland foods and separating drinks from meals tend to help.

Weight is worth tracking at home on the same scale each week. A dry mouth that makes chewing tiring, combined with nausea and fatigue, can quietly erode intake across a course of treatment. A referral to a dietitian early in the course is a reasonable request, not a sign of failure. Taste changes usually settle between cycles but can linger.

Radiation safety at home in the first days after treatment

For a short period after each infusion, a treated man is mildly radioactive. Lutetium-177 has a physical half-life of about six and a half days, meaning half of it decays in that time, and the body also clears unbound drug through urine. The gamma component is weak, so the risk to others is low, but it is not zero, and sensible precautions are standard practice.

Specific instructions vary between countries and centers, and the team’s written sheet always takes priority. Typical advice covers:

  • Keeping a comfortable distance from others for the first few days, especially avoiding prolonged close contact with young children and anyone who is pregnant.
  • Sleeping in a separate bed for a few nights if practical.
  • Sitting to urinate, flushing twice with the lid down and washing hands thoroughly, since urine carries most of the excreted drug.
  • Washing clothing and bed linen separately if there is any spill of body fluid.
  • Carrying the treatment card when traveling, because airport and border radiation detectors can register the isotope for weeks.

These measures are about minimizing exposure to family and the public, not about danger to the patient. Partners often worry about hugging or sharing a sofa; short contact is generally considered acceptable, and the team can give distances and durations specific to the amount administered.

The precautions also explain a commonly misunderstood point. Feeling unwell in the first days is not a sign that radiation is ‘leaking’ or that something has gone wrong. It reflects the drug doing its work at PSMA-rich sites, including the ones it was never meant to visit. Any symptom that concerns you is worth a call, but the radioactivity itself is expected, temporary and measurable.

What the days and weeks after each cycle usually look like

Timelines below are typical ranges drawn from trial reports and clinical guidance, not a schedule any individual should expect to follow exactly.

Infusion day and the day after. The infusion is brief, often followed by a short observation period and sometimes a scan to confirm distribution. Most men feel much as they did that morning. Nausea, if it comes, tends to start here, along with the first hint of a dry mouth. Radiation precautions at home begin immediately.

Days two to seven. Fatigue builds. Some men notice a temporary flare of bone pain at known sites, thought to reflect inflammation as cancer cells break down; it usually settles within a week or two and is worth reporting so pain relief can be adjusted. Taste changes and reduced appetite are common.

Weeks two to four. Blood counts typically reach their lowest point in this window. Most men feel this only as tiredness, but this is when bruising, nosebleeds or a fever matter most. Dry mouth may plateau or ease slightly.

Before the next cycle. Blood tests and kidney function are rechecked, along with a discussion of how the previous weeks went. The team decides whether to proceed on time, delay or stop. A PSA blood test is often tracked, though it is one signal among several and can lag behind what imaging shows.

Across a full course, the pattern often repeats with a slowly lowering baseline of energy, and dry mouth tends to be cumulative rather than resetting fully. After the final cycle, counts usually recover over weeks to months, fatigue lifts gradually, and follow-up scans and blood tests continue at intervals the team sets. Men who kept a simple diary of symptoms and dates during treatment consistently found those appointments easier.

How long does lutetium extend life? What the evidence actually shows

This is the question most men and families are really asking, and it deserves a straight answer about what the data can and cannot say.

The VISION trial randomized 831 men with PSMA-positive metastatic castration-resistant prostate cancer who had already progressed on hormone-pathway therapy and chemotherapy. Those who received lutetium-177 PSMA-617 plus standard care lived a median of 15.3 months, compared with 11.3 months for standard care alone. Median time before the cancer progressed on imaging was 8.7 months versus 3.4 months. A second randomized trial, TheraP, compared the therapy with cabazitaxel chemotherapy and found that more men had a PSA fall of at least half with the radioligand, alongside fewer severe side effects, though it was not designed to show a survival difference.

Three cautions matter when reading those numbers. A median is the midpoint: half the men in the trial lived longer than 15.3 months, some considerably longer, and half did not reach it. The comparison group in VISION received best available care but not further chemotherapy, so the gap may differ in other settings. And trial participants were selected for fitness, adequate blood counts and kidney function, which does not describe everyone offered treatment in routine practice.

There is no honest ‘success rate’ for this or any advanced cancer therapy, because success means different things: shrinking tumors, easing bone pain, holding PSA steady, or simply buying comfortable time. The therapy is a way to treat and control disease, not to eliminate it. Asking the team what response would look like for you, and how they would recognize that it is not working, produces a more useful conversation than any single percentage.

What about PSMA PET scan side effects?

Confusion between the scan and the treatment is understandable, because both use a PSMA-targeting molecule. The difference is what is attached to it. For a PET scan, the molecule carries a short-lived positron-emitting tracer, commonly gallium-68 or fluorine-18, in a tiny amount designed only to be seen by the camera. For treatment, it carries lutetium-177 in a far larger amount designed to damage cells.

The scan tracer therefore produces essentially none of the effects discussed in this article. It does not cause dry mouth, fatigue or changes in blood counts. Reported side effects in imaging studies are uncommon and typically limited to mild discomfort at the injection site, a brief metallic taste or, very rarely, an allergic-type reaction, which is why patients are observed for a short time after injection. The radiation exposure from the scan is in the range of other nuclear medicine and CT examinations and is considered acceptable for the diagnostic information it provides; the imaging team can give you the specifics for your protocol.

A few practical points do apply. The tracer is cleared largely through the urine, so drinking water and emptying the bladder afterward are usually encouraged, and brief precautions around pregnant women and infants for the rest of the day are sometimes advised. Men are often asked to lie still for a period after injection so the tracer distributes evenly.

The scan’s real limitation is interpretive rather than physical. Uptake in salivary glands, kidneys, bowel and some benign conditions is normal and can occasionally be mistaken for disease, and a small proportion of prostate cancers display little PSMA and are missed. That is why the treating team reads the PSMA PET alongside conventional CT and bone imaging before deciding whether treatment is appropriate.

What people often get wrong about lutetium PSMA therapy

‘It targets only cancer, so there are no side effects.’ The targeting is real but imperfect. PSMA lives on salivary glands, kidneys and gut cells too, and circulating radiation reaches bone marrow. About half of treated men in VISION had at least one severe adverse event.

‘It is a last resort with nothing to lose.’ It is currently used late in the disease, but the decision still involves trade-offs. Marrow reserve spent on this treatment may not be available for a later chemotherapy. That is exactly the kind of judgment the team makes with you.

‘A rising PSA in the first weeks means it has failed.’ PSA can fluctuate as cells break down, and imaging response sometimes lags. Teams usually judge response over more than one cycle, using scans, symptoms and blood work together.

‘Dry mouth is trivial.’ For most men it is mild, but it is the effect most likely to persist after treatment ends, and it affects eating, sleep and dental health. It deserves early attention rather than stoic silence.

‘The radiation makes me dangerous to my family.’ The precautions are about keeping others’ exposure as low as reasonably possible for a few days. Short contact is generally acceptable; the team will specify.

‘The scan and the treatment carry the same risks.’ The PET tracer is a diagnostic trace amount and does not cause the fatigue or blood count changes of treatment.

‘Lung inflammation is common.’ Pneumonitis, an inflammation of lung tissue, has appeared in a handful of case reports. It is rare, but new cough or breathlessness should be reported promptly precisely because it is unexpected.

‘Ice packs on the cheeks are proven to protect the salivary glands.’ Small studies have been inconsistent. It is an open question, not an established safeguard.

Questions to ask your care team

Consultations are short and the vocabulary is dense, so a written list helps. These questions are drawn from what men and partners most often say they wished they had asked earlier.

  • What did my PSMA PET show, and were there any areas of cancer that did not take up the tracer?
  • How are my blood counts and kidney function now, and what changes would make you delay or stop a cycle?
  • Which of the common side effects are you most concerned about in my case, given my previous treatments?
  • How will you judge whether the treatment is working, and when will you make that judgment?
  • If it is not working, what are the realistic next options, and does this treatment change any of them?
  • Should I see a dentist before the first cycle, and what mouth care do you recommend during treatment?
  • How much should I drink around each infusion, and is that safe with my heart or kidney history?
  • What exactly are the radiation precautions at home, for how long, and what about my grandchildren?
  • Who do I call, at any hour, if I develop a fever or bleeding, and what number do I use?
  • Is there a clinical trial I should know about, either instead of or alongside this treatment?
  • Can you refer me to a dietitian or a physiotherapist for fatigue management?
  • If I develop bone pain in the first week, is that expected, and how should I manage it?

Bring a second person if you can. Partners often remember different halves of the same conversation, and the combination is usually more complete than either alone. Asking the team to write down the three most important things to watch for in the next fortnight is a small request that pays off.

When to call your doctor

Most lutetium PSMA therapy side effects are expected and manageable, but a few signs point to problems that need same-day assessment, and some need emergency care. Your treatment center will have given you a direct number; use it. Do not wait for the next scheduled appointment if you notice any of the following.

Seek emergency care for chest pain, sudden severe breathlessness, fainting, confusion, a seizure, heavy bleeding that will not stop, black or bloody stools, vomiting blood, or sudden weakness or numbness on one side of the body.

Call the team the same day for:

  • A fever, chills or shivering, however mild you feel otherwise; with low white cells, infection can escalate within hours.
  • Unexplained bruising, nosebleeds, bleeding gums or a rash of tiny red dots, which can signal low platelets.
  • New or worsening breathlessness, a persistent cough or breathlessness when lying flat.
  • Passing much less urine than usual, swelling of the legs or ankles, or blood in the urine.
  • Inability to keep fluids down for more than a day, or signs of dehydration such as dizziness on standing and very dark urine.
  • Fatigue so severe that you cannot get out of bed or manage basic self-care.
  • New back pain with leg weakness, numbness, or loss of bladder or bowel control, which can indicate pressure on the spinal cord from bone disease and is an emergency.
  • A mouth so dry or sore that you cannot eat, or white patches suggesting thrush.

Mention that you are receiving radioligand therapy whenever you contact any healthcare service, including emergency departments, so that radiation precautions can be observed and blood tests interpreted correctly. Every decision about continuing, pausing or changing treatment rests with your treating team, and they would far rather hear from you early than late.

Frequently asked questions

How long does lutetium extend life?

In the VISION randomized trial, men who received lutetium-177 PSMA-617 plus standard care lived a median of 15.3 months compared with 11.3 months for standard care alone, a difference of about four months at the midpoint. Half of treated men lived longer than that median and half did not. Individual outcomes depend on how much cancer displays PSMA, overall fitness, blood counts and kidney function, so your team’s estimate for you is more meaningful than the trial average.

What is the success rate of lutetium 177 PSMA therapy?

There is no single success rate, because success can mean tumor shrinkage, a PSA fall, pain relief or time without progression. In the TheraP trial, more men had a PSA fall of at least half with the radioligand than with cabazitaxel chemotherapy, and in VISION imaging-based progression was delayed from a median of 3.4 to 8.7 months. The therapy treats and controls advanced disease; it is not expected to eliminate it.

What is the most successful prostate cancer treatment?

No treatment is best for everyone, because prostate cancer ranges from slow-growing disease that may only need monitoring to widespread cancer needing several therapies in sequence. Surgery, radiation, hormone therapy, chemotherapy and radioligand therapy each suit different stages and different men. Lutetium PSMA therapy is currently used after hormone-pathway drugs and chemotherapy in men whose cancer displays PSMA. Your multidisciplinary team matches treatment to stage, fitness and priorities.

What are the side effects of a PSMA PET scan?

PSMA PET scan side effects are uncommon and mild, because the tracer is a diagnostic trace amount rather than a therapeutic one. Reported effects include brief discomfort at the injection site, a temporary metallic taste and, very rarely, an allergic-type reaction. The scan does not cause dry mouth, fatigue or blood count changes. Radiation exposure is comparable to other nuclear medicine imaging, and drinking water afterward helps clear the tracer through the urine.

Does lutetium 177 dry mouth go away?

For many men, dry mouth eases between cycles and improves in the months after treatment ends, but in some it persists, and it tends to build across a course rather than fully resetting. In VISION it was almost always mild or moderate. Regular sips of water, sugar-free gum, saliva substitutes and careful dental care help. Report it early so your team can weigh symptom burden against benefit before the next cycle.

How long does Lu-177 PSMA therapy fatigue last?

Fatigue typically builds over the first few days after an infusion, peaks within about one to two weeks and eases before the next cycle, though the baseline often drifts lower as cycles accumulate. After the final cycle, energy usually returns gradually over weeks to months. The team checks hemoglobin before each cycle because anemia is a treatable contributor. Gentle regular activity, pacing and protected sleep have the best evidence for reducing cancer-related fatigue.

Why are blood tests done before every cycle?

Because lutetium-177 irradiates bone marrow as it circulates, red cells, white cells and platelets can fall in the weeks after each infusion. A complete blood count and kidney function tests before each cycle show whether the marrow and kidneys have recovered enough to proceed safely. If they have not, the team may delay, adjust or stop treatment. These thresholds are set by the treating physician for each individual.

Is it safe to be around family after lutetium PSMA treatment?

Yes, with short-term precautions. For a few days you emit low-level radiation and excrete the drug in urine, so teams typically advise keeping some distance from others, especially young children and pregnant women, sleeping separately for a few nights, and careful toilet hygiene. Brief contact such as a hug is generally considered acceptable. Follow your center’s written instructions, which are tailored to the amount you received.

Can lutetium PSMA therapy damage the kidneys?

The kidneys display PSMA and also clear the drug, so they receive radiation from both routes. In the VISION trial about 9% of treated men had a kidney-related adverse event, most of them mild. Long-term data are still being gathered, which is why creatinine and filtration rate are checked before every cycle and afterward. Good hydration around infusions helps flush unbound drug, with fluid targets set by your clinician.

What happens if my blood counts are too low to continue?

The team usually delays the next cycle to let the marrow recover, and may reduce the amount given or stop the course if counts do not rebound. A transfusion can be offered for symptomatic anemia. A pause is a safety measure, not a sign the treatment has failed. Men with extensive bone disease or many prior chemotherapy cycles are watched most closely because their marrow reserve is smallest.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 22, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.